8-K: Athira Pharma Announces Restructuring, Focus on ATH-1105 Development

Athira Pharma is reducing its workforce by 70% and focusing on the development of ATH-1105 for neurodegenerative diseases, including ALS.

Summary

• Athira Pharma is restructuring its operations to focus on the development of ATH-1105, a drug candidate for neurodegenerative diseases.
• The company is reducing its workforce by approximately 70%, which equates to about 49 positions.
• This restructuring is expected to result in one-time costs of approximately $2.8 million, primarily for severance and termination benefits.
• The company anticipates annual cost savings of approximately $13.4 million due to the workforce reduction.
• The restructuring is expected to be substantially completed by December 31, 2024.
• Athira expects its cash runway to extend into the first quarter of 2026 as a result of these cost containment measures.
• The company is also exploring options such as partnering and financing to further extend its cash runway.
• The company has terminated the employment of its chief business officer and chief financial officer, and its chief operating officer and chief development officer, effective October 1, 2024.
• Robert Renninger, the vice president of finance, has been appointed as the principal financial officer and principal accounting officer, effective October 1, 2024.

Sentiment

Score: 4

Explanation: The document indicates a significant restructuring with a large workforce reduction and executive departures, which are generally negative signals. However, the focus on a promising drug candidate and the extension of the cash runway provide some positive aspects. Overall, the sentiment is cautiously negative due to the restructuring and potential financial challenges.

Positives

• The company is streamlining operations to focus on its most promising drug candidate, ATH-1105.
• The cost containment measures are expected to extend the company's cash runway into the first quarter of 2026.
• The company is actively exploring options to further extend its cash runway, including partnerships and financing.
• ATH-1105 has shown promising preclinical data, including neuroprotective effects and reduction in plasma neurofilament light chain (NfL) levels.
• The company has completed the first cohort of healthy volunteers in the Phase 1 trial for ATH-1105.

Negatives

• The company is reducing its workforce by a significant 70%, which will impact approximately 49 employees.
• The company will incur one-time costs of approximately $2.8 million due to the restructuring.
• The company has terminated the employment of two executive officers.
• The company is still in the early stages of clinical development for ATH-1105, with dosing of ALS patients expected in 2025.

Risks

• The restructuring may not be implemented successfully or may incur greater costs than estimated.
• The company may not achieve the anticipated cost savings from the workforce reduction.
• The company may not be able to secure partnerships or financing on commercially reasonable terms.
• Clinical trials for ATH-1105 may not be successful, and the drug may not receive regulatory approval.
• The company's assumptions regarding its financial condition and cash runway may be incorrect.
• The company faces competition from other companies developing treatments for neurodegenerative diseases.

Future Outlook

Athira plans to focus on advancing the clinical development program for ATH-1105, including the commencement of dosing ALS patients in 2025. The company will also review and consider various options including partnering and financing with the intent of extending its cash runway to achieve initial proof-of-concept and enable further development for ATH-1105 in neurodegenerative diseases.

Management Comments

• Mark Litton, Ph.D., President and Chief Executive Officer of Athira, stated that they are encouraged about the potential for ATH-1105 due to its enhanced blood-brain-barrier penetration and improved pharmacokinetic properties.
• Javier San Martin, M.D., Chief Medical Officer of Athira, noted that in ALS, plasma NfL is an established marker of disease progression and neurodegeneration, and reduction in NfL is associated with improvement in clinical outcomes.
• Dr. Litton thanked the departing colleagues for their contributions to the development of therapeutics that modulate the neurotrophic HGF system.

Industry Context

This announcement reflects a shift in focus for Athira Pharma, moving away from the Alzheimer's disease program and towards the development of ATH-1105 for ALS and other neurodegenerative diseases. This is a common strategy in the biotech industry where companies prioritize their most promising assets and cut costs to extend their runway. The focus on HGF modulation and reduction of NfL levels aligns with current research trends in neurodegenerative disease therapeutics.

Comparison to Industry Standards

• The workforce reduction of 70% is a significant cut, which is not uncommon for biotech companies undergoing a strategic shift or facing financial constraints. For example, companies like Biogen and Sage Therapeutics have also implemented workforce reductions in recent years to streamline operations and focus on key programs.
• The focus on ATH-1105 and its potential for ALS treatment aligns with the industry's growing interest in developing therapies for neurodegenerative diseases. Companies like Amylyx Pharmaceuticals and Biogen have recently received approvals for ALS treatments, indicating a market need and potential for success.
• The estimated $2.8 million in one-time costs for severance is within the typical range for companies undergoing similar restructuring. However, the $13.4 million in annual cost savings is a substantial amount and will be critical for extending the company's cash runway.
• The company's cash runway extending into the first quarter of 2026 is a positive development, but it is important to note that many biotech companies require additional funding to reach commercialization. Companies like Cassava Sciences and Anavex Life Sciences are examples of companies that have had to raise additional capital to fund their clinical programs.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the significant workforce reduction and executive departures.
• Employees are significantly impacted by the workforce reduction, with approximately 70% of the workforce being terminated.
• Customers and partners may be impacted by the shift in focus and potential delays in other programs.
• Creditors may be concerned about the company's financial stability and ability to repay debts.

Next Steps

• The company will substantially complete the restructuring by December 31, 2024.
• The company will continue the Phase 1 clinical trial for ATH-1105, with completion expected by year-end 2024.
• The company plans to begin dosing ALS patients in 2025.
• The company will review and consider various options including partnering and financing to extend its cash runway.

Key Dates

Keywords

ATH-1105, neurodegenerative diseases, amyotrophic lateral sclerosis, ALS, workforce reduction, restructuring, cost containment, clinical trial, HGF modulation, severance, executive changes, cash runway, biopharmaceutical